The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (IDA) indications included in the submission data.
Investor deep dive
Shield Therapeutics: All eyes on the US after FDA approval
Broad label approval is 'best possible outcome' for Shield Therapeutics' Feraccru
Quick facts: Shield Therapeutics PLC
Price: 182.5 GBX
Market Cap: £213.87 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE